Credit: Shutterstock. Adlarity is a once-weekly transdermal formulation of donepezil that is designed to be worn for 7 days with consistent adhesion. The Food and Drug Administration (FDA) has ...
The prescribed dosage for Aricept (donepezil) may depend on a person’s individual treatment plan. Factors such as the person’s medical history and condition may affect the dosage of Aricept. Aricept ...
TOKYO and WOODCLIFF LAKE, N.J., March 28 /PRNewswire/ -- Eisai Co., Ltd. and its U.S. subsidiary Eisai Inc. (collectively "Eisai") today announced that the United States District Court for the ...
April 2, 2012 — Approval for the new 23-mg dose of the Alzheimer's disease (AD) drug donepezil (Aricept, Eisai) "breached the FDA's own regulatory standard" and has led to "incomplete and distorted ...
The acetylcholinesterase inhibitor donepezil (Aricept) failed to improve chemotherapy-related cognitive impairment (CRCI) in breast cancer survivors, a placebo-controlled trial showed. After 24 weeks ...
WOODCLIFF LAKE, N.J. & NEW YORK--(BUSINESS WIRE)-- Eisai Inc. and Pfizer Inc [NYSE: PFE] announced today that the U.S. Food and Drug Administration (FDA) approved a new once-daily, higher-dose Aricept ...
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for the Aricept ® Patch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results